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A greatly expanded understanding of the biology of
endogenous erythropoietin (EPO) has emerged since the
early 1990s. Originally viewed as the renal hormone
dedicated to erythrocyte production, it is now clear that EPO
is produced locally by many other tissues in response to
physical or metabolic stress. In its autocrine–paracrine roles,
EPO mediates preconditioning (ischemic tolerance) and
specifically limits the destructive potential of tumor necrosis
factor a and other proinflammatory cytokines in the brain,
heart, kidney, and other tissues. As local production of EPO is
generally suppressed following injury, administration of
exogenous EPO has been a successful therapeutic approach
in preclinical and clinical studies, for example, following
ischemia–reperfusion and toxin-induced renal injuries, and in
human stroke. The therapeutic time window of tissue
protection by EPO is typically very wide in experimental
models, showing effectiveness when administered before,
during, or after an insult and raising optimism for a high
clinical potential. Although there is progress in
understanding the signaling pathways responsible for EPO’s
tissue-protective actions that are similar to, but not as
redundant as, those employed for erythrocyte maturation,
much work remains to be carried out. Experimental
observations also suggest the existence of EPO receptor
(EPOR) isoforms mediating EPO’s diverse biological activities
and have identified a tissue-protective receptor complex
consisting of the EPOR and the beta common receptor
(CD131) subunit that is also employed by
granulocyte–macrophage colony-stimulating factor,
interleukin-3 and interleukin-5. Successfully engineered
analogues of EPO that selectively activate tissue protection
without stimulating hematopoiesis confirm the concept of a
tissue-protective receptor and have significant potential
utility in the investigational and therapeutic arenas.
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ENDOCRINE VERSUS PARACRINE
Classic studies established long ago that the adult kidney is
the source of the circulating erythropoietin (EPO) that
maintains erythrocyte mass (reviewed by Fisher1). In this
role, EPO prevents programmed cell death (apoptosis) of
erythrocyte precursors in a negative feedback control fashion,
typical of an endocrine hormone. However, beginning with
the unexpected observations of EPO receptor (EPOR)
expression by the endothelial cell2 and within the central
nervous system,3 as well as the capacity for EPO production
by astrocytes,4 a broader concept of EPO as a paracrine–
autocrine tissue-protective molecule has emerged over the last
15 years. Simply put, metabolic stress triggers apoptosis in
tissues as an adaptive response to limit the spread of infection
by destroying surrounding tissue and EPO is an antagonist of
this biological process (reviewed by Brines and Cerami5).
This innate immune response works well with true infection,
but results in more damage in the setting of trauma,
ischemia, or toxins through excessive apoptosis of viable
tissue within the region immediately surrounding an injury.
Further, EPO also antagonizes the activities of proinflam-
matory cytokines and promotes healing following injury
(e.g., by stimulating capillary growth). However, because of a
significant temporal delay in EPO gene expression after an
injury (hours) and the direct suppression of EPO production
by inflammatory cytokines, a maximum protective benefit is
only achieved by administration of exogenous EPO.
An initial understanding of the biology of EPO-mediated
tissue protection largely developed from study of the nervous
system, a tissue of a high basal metabolic rate and therefore
an enhanced susceptibility to ischemic injury. The findings
derived from the nervous system, however, also broadly apply
to other tissues and organs. Like the nervous system, the
normal kidney is characterized by regions in which energy
substrates are limited. Commonly, chronic renal hypoxia
with subsequent tubulointerstitial injury establishes a vicious
cycle leading if not prevented to end-stage renal failure.
Principal mediators of injury are highly reactive free radicals
produced as by-products of cellular metabolism under
relative hypoxic condition. Endogenous, locally produced
EPO is active in preventing injury under these circumstances.
Mechanistically, hypoxia activates the hypoxia inducible
factor (HIF) family of proteins that turn on a number of
protective genes, including EPO (reviewed by Maxwell6).
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Direct activation of HIF-1, for example by mild ischemia in
advance of potential injury, provides considerable protection
from subsequent actual injury. However, HIF-1-activated
gene expression is actually relatively sluggish considering the
pathological processes that injury triggers. Additionally, HIF-
1 activation also includes molecules that can produce
maladaptive effects, such as vascular endothelial growth
factor-induced vasogenic edema. Many studies have shown
that exogenous EPO administered before or after injury is
highly effective for the prevention of permanent or transient
ischemic injury in multiple organs and tissues. The findings
from studies of ischemic injury appear to apply generally to
other forms of injury, including trauma, toxins, and infection
(Figure 1; reviewed by Brines and Cerami5).
EPO AND THE KIDNEY
A potential role for the non-hematopoietic activities of EPO
in the kidney was first implied by the identification of EPOR
protein expressed throughout the kidney, including both
proximal and distal tubular cells.7 However, the affinity of
these receptors (B1 nM) is well below the normal plasma
EPO concentration (B1–10 pM), consistent with observations
in other tissues responding to EPO in a paracrine fashion.
These receptors have such a low probability of occupancy by
circulating EPO that they are functionally isolated from the
hematopoietic system. However, it is currently unclear what
contribution (if any) to the local intra-renal EPO content is
provided by the fibroblast-like interstitial cells that produce
circulating EPO. It will be interesting to examine the
pharmacological characteristics of the EPOR within this
microdomain.
EPO administration elicits physiological effects within the
normal kidney not primarily associated with tissue protec-
tion and these could have important implications in certain
clinical situations. One prominent EPO target is the vascular
smooth muscle cell (VSMC) in which EPO increases
intracellular calcium and causes VSMC contraction in vitro
and constriction in vivo, significantly increasing peripheral
vascular resistance.8 Clinically, EPO has variable effects on
systemic blood pressure and vascular resistance.9 A sub-
stantial proportion (B35%) of patients with end-stage renal
disease will exhibit a dose-dependent increase in blood
pressure following EPO administration. Observations using
preclinical models have been variable, with some groups
finding large increases in blood pressure and others only
moderate or no effect.9 Some blood pressure effects may arise
from modulation of nitric oxide production, as EPO has been
reported to induce changes in nitric oxide synthase directly or
indirectly by stimulating the production of asymeterical
dimethyl arginine, an endogenous inhibitor of nitric oxide
synthase. Further, acute EPO administration reduces cortical
renal blood flow and urinary solute excretion.9 However,
potential effects on renal nerves apparently have not been
assessed. Any or all of these effects could be important in the
setting of injury, but have not been extensively studied.
THE CAPILLARY ENDOTHELIUM
Capillary endothelial cells obtained from a variety of tissues
express EPO and EPOR and were the first cells implicated
experimentally as targets of the extra-hematopoietic activities
of EPO.2 Endothelial cells respond to local ischemia by
producing EPO. Therefore, these cells distributed universally
throughout tissues could potentially provide EPO-mediated
protective function globally. The endothelial cell expresses a
receptor with an affinity for EPO (B1 nM) intermediate
between the erythrocyte precursor (B200 pM) and neuronal
cells (B10–20 nM). Regulation of the endothelial cell EPO/
EPOR has been studied, and under hypoxia, EPO strongly
stimulates the expression of EPOR.10 For tissues characteri-
zed by a relatively impermeant endothelial barrier, such as the
blood–brain barrier, EPO has been shown to increase cell
surface proteins maintaining tight junctions in vitro.11 A large
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Figure 1 | Examples of gross pathology exhibiting beneficial effects of EPO or the non-erythropoietic molecule carbamylated EPO
(CEPO) for tissue injury models in rodents. (a) EPO administered as a single dose (5000 U/kg-bw intraperitoneally) immediately following
traumatic injury to mouse brain markedly reduces tissue loss (left) when evaluated 10 days following injury (reproduced with permission from
Proc Natl Acad Sci USA). (b) Cross-sections of the heart obtained 24 h following injury from a rat model of myocardial ischemia (30 min)
with reperfusion administered carbamylated EPO (10 mg/kg-bw at reperfusion). Masson trichrome staining shows intact muscle (red) and scar
(blue). (c) Carbamylated EPO (10 mg/kg-bw intravenously at reperfusion) protects rat kidney from 60 min of ischemia (renal artery occlusion)
followed by reperfusion for 48 h. The vehicle-treated kidney is severely necrotic, exhibiting widespread tubular destruction (original
magnification  100).
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contribution to tissue protection following injury is likely
attributable to EPO-mediated survival of the capillary
endothelium itself from destruction by microinfarction.
EPO also strongly mobilizes and regulates endothelial
progenitor cells9,12 and recent interest has focused on a
potential principal role of EPO in endothelial progenitor cell
recruitment, enhancement of adhesiveness, proliferation, and
promoting repair of the endothelium as well as angiogenesis
in the setting of tissue injury.
EPO AND RENAL INJURY
A number of groups have shown that EPO or darbepoietin
administered in preclinical models at high dose (300–5000 U/
kg-bw intraperitoneally) is substantially protective of ischemia–
reperfusion injury as assessed by residual renal function and
histological markers of injury (reviewed by Chatterjee13).
Similar to its effects in nervous tissue, EPO strongly sup-
presses the inflammatory response to ischemia–reperfusion in
the kidney, reducing proinflammatory cytokine production,
subsequent leukocyte recruitment, and amplification of
damage. EPO is also renoprotective against toxins such as
cyclosporine and cisplatin (reviewed by Chatterjee13). In
these acute experiments, there were no increases in hemo-
globin concentration so that the action of EPO was a direct
one on the kidney.
A number of clinical trials have concluded that early EPO
administration to predialysis patients slows the progression
of kidney disease. However, the chronic administration of
EPO also increases hemoglobin levels and complicates
assignment of cause and effect. For example, one clinical
trial in which the efficacy of EPO was evaluated in a
predialysis population observed that patients in the EPO arm
had a 60% reduction of the risk of initiating renal
replacement or death.14 However, as the EPO group also
had a higher hemoglobin concentration (12.9 versus 10.3),
the beneficial effect of receiving EPO was ascribed to the
increased erythrocyte number. In contrast to studies where
patients received EPO chronically, virtually no clinical studies
concerning tissue protection following acute EPO adminis-
tration exist. One exception is a successful proof of concept
trial of EPO in human stroke. In this study, EPO (100 000 U
administered intravenously, divided over 3 days) has been
shown to be effective for improving the short-term clinical
outcome of patients with middle cerebral arterial infarction,
without any acute changes in hemoglobin concentrations.15
Further clinical trials will need to be designed with the
potential direct or indirect effects in mind.
PHARMACOLOGICAL APPROACHES TO TISSUE PROTECTION
Although EPO presumably is the only endogenous ligand
mediating tissue protection though the EPOR, its therapeutic
utility could be complicated by increases in red cell mass and
development of a prothrombotic state. One approach to
avoid this problem arose from an appreciation that effective
production of erythrocytes requires a continuous presence
of EPO in the circulation.16 The EPO molecule is highly
glycosylated and the sialic acid moieties terminating the
oligosaccharide chains prevent rapid clearance from the
plasma. Selective tissue protection without activating ery-
thropoiesis can be accomplished using desialated EPO which
has a very short half-life. In multiple preclinical models, this
analogue demonstrates potent tissue protection without any
detectable stimulation of the bone marrow.16 AsialoEPO is
also a useful reagent to assess whether components of tissue
protection depend upon triggering gene expression, as this
compound disappears from the circulation after several
minutes.
Another approach for selectively targeting tissue protec-
tion was predicted from the mismatch between the affinity of
the non-hematopoietic, tissue EPO receptor and the much
lower levels of circulating EPO. EPO is a member of the
type 1 cytokine superfamily that is characterized by multi-
functionality mediated by different assemblages of receptor
subunits. Our group has identified signaling via a putative
EPO receptor isoform different from the homodimer
mediating erythropoiesis, consisting of a heteromeric com-
plex containing EPOR and the beta receptor subunit
(CD131) common to granulocyte–macrophage colony-
stimulating factor, interleukin-3, and interleukin-5.17 This
was substantiated by demonstrating that knockout of the beta
common receptor gene fully abolishes tissue protective
properties of EPO in the nervous system and heart.
The presence of another receptor isoform clearly raises the
possibility of developing ligands with differential affinity to
receptor subtypes. The EPO receptor isoform that transduces
erythropoiesis has been extensively studied and consists of a
preformed homodimer to which EPO binds via two well-
defined sites.18 The interaction between EPO and its homo-
dimeric receptor isoform can be abolished by chemical
modification of lysine, or mutation of critical amino-acid
residues within the binding sites. Engineered molecules so
produced exhibit no affinity for the homodimeric EPO
receptor isoform, as expected, but are equipotent to EPO for
protection of tissues from injury.16
MECHANISMS OF TISSUE PROTECTION
Abundant evidence has accumulated in studies of injury in
the nervous system and heart that EPO is antiapoptotic,
similar to its endocrine actions within the bone marrow.
Additionally, EPO has a marked effect on inflammatory
processes stimulated by injury (reviewed by Brines and
Cerami5). In some cases, for example, cerebral cortical
ischemia and reperfusion,19 anti-inflammatory effects arise
secondarily via a reduction of primary injury that in turn
reduces the production of proinflammatory cytokines such as
tumor necrosis factor a. In other models, EPO has a direct
effect on proinflammatory cytokine production.20 The
precise interaction and relative importance of each pathway
likely differs for each specific tissue. The implication of
locally produced tumor necrosis factor as a major factor in
the pathophysiology of renal ischemia–reperfusion injury
(reviewed in Donnahoo et al.21) suggests that EPO is likely to
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reduce renal injury partly by inhibiting proinflammatory
cytokines. It is notable that recent work also shows that in
some tissues suppression of proinflammatory cytokine
expression alone (e.g., by glucocorticoids in the spinal
cord22) is not sufficient to prevent tissue injury. Thus, the
contribution of anti-inflammatory effects to injury reduction
may be less than that initially thought. EPO may also directly
stimulate other protective molecules, for example, BDNF,
which explains some of the beneficial effects of EPO within
the nervous system.23
CELLULAR MEDIATORS OF PROTECTION
Multiple, complicated, and often conflicting observations
have been made concerning signaling pathways activated by
EPO in mediating tissue protection. Much of the early
investigation was driven by knowledge of pathways activated
in the prevention of apoptosis of erythrocyte precursors and
not surprisingly, similarities were identified. Subsequent
study has identified certain pathways not shared. Undoub-
tedly, some observed differences derive from the tissue or cell
studied and the particular methodology employed. Unlike
erythropoiesis, survival pathways do not appear to be
redundant, as inhibition of any single pathway generally
blocks tissue protection.
Three main signaling pathways are involved in mediating
tissue protection (reviewed by Brines and Cerami5). (1) The
Jak2-STAT-Bcl-2 pathway, a dominant EPO-dependent anti-
apoptotic mechanism for hematopoietic cells, also has been
implicated in tissue protection. A number of investigators
have identified regulation of this pathway, either by induction
of antiapoptotic molecules (Bcl-2 and Bcl-XL) or decrease
in proapoptotic molecules (bax, bak). (2) EPO-mediated
activation of the survival kinases extracellular signal-regu-
lated kinase and Akt are critical in the nervous system. The
neuroprotective effect of EPO involves the Ras/mitogen-
activated protein kinase or the phosphatidylinositol 30-kinase
pathway and selective inhibitors of mitogen-activated protein
kinase and phosphatidylinositol 30-kinase block the phos-
phorylation of extracellular signal-regulated kinases and Akt/
Protein kinase B and prevent the effect of EPO, as has been
shown by multiple workers using different model systems
in vitro and in vivo. (3) The nuclear factor-kB system: Jak2-
dependent activation of nuclear factor-kB has been proposed
to mediate neuroprotection of cortical neurons in vitro as
inhibition of these messengers blocked protection. Activation
of nuclear factor-kB has also been implicated by others,
although some studies suggest that nuclear factor-kB does
not play a role in the antiapoptotic effect of EPO for certain
neuronal cell lines.
An additional comment concerning tissue protection
pathways is warranted. For some of these pathways, EPO
was shown to reverse the decrease in these pathways induced
by the noxious stimulus, rather than directly activating the
pathway. This was shown, for instance, in hippocampal
neurons in vitro where hypoxia decreased the expression of
the phosphorylated forms of Stat5, Akt, and extracellular
signal-regulated kinase, and EPO restored their levels.24
Further examination of signaling mechanisms is warranted.
TIMING AND DOSAGE CONSIDERATIONS FOR TISSUE
PROTECTION
Optimum timing and size of dose required for tissue
protection has been incompletely explored and likely is
significantly tissue-specific. Clearly, the presence or absence
of receptors for EPO within the target tissue at baseline is a
critical issue. In general, EPO and non-erythropoietic tissue-
protective cytokines do not appear to directly modulate
EPOR levels in normal tissues. However, in the setting of
hypoxia, EPO has been observed to increase message for its
own receptor in endothelial cells.10 Some tissues have only
low levels of EPOR in the absence of ischemia (e.g., cerebral
cortex). Pretreatment by EPO or its tissue-protective
analogues provides significant protection in some tissues,
for example, the heart, in which exposure either immediately
(o1 h; activating acute preconditioning) or 24 h before
(triggering delayed preconditioning) reduced subsequent
ischemic–reperfusion injury (reviewed by Baker25). The
possibility for successful prevention of tissue damage by
pretreatment with EPO is obviously attractive for addressing
iatrogenic injury, such as that produced by surgical
procedures.
With respect to dosing, generally most preclinical models
have used very high doses compared to that used for
treatment of anemia (but there are exceptions, e.g. Bahlmann
et al.26 used 0.1 mg/kg of darbepoietin to attenuate progres-
sive renal failure in a 5/6 rat nephrectomy model). The use of
high doses became standard presumably arose because the
central nervous system was the first organ for which
peripheral administration of EPO was shown to protect
from injury.27 For tissues characterized by tight endothelial
barriers, like the central nervous system, minimum effective
doses of EPO are very high B500 U/kg-bw administered
intraperitoneally or intravenously. Other tissues, for example,
the heart and kidney, have much lower minimum effective
doses falling within the dosing range typically employed
clinically for the treatment of anemia (10–50 U/kg-bw;
reviewed by Chatterjee13). Much more work needs to be
carried out concerning dose-ranging and pharmacodynamics
using preclinical models appropriate for supporting potential
clinical studies.
FUTURE PROSPECTS
Abundant preclinical data are supportive of a potential role
for EPO in treatment of clinical diseases of diverse etiology.
Although attempted translation of these findings into the
clinic has only just started, a successful proof of concept trial
in stroke caused by middle cerebral artery occlusion is
reassuring. Many investigator-initiated trials for a number of
indications (e.g., multiple sclerosis, stroke, and acute
myocardial infarction) are currently underway and will
provide additional information with which to conduct
further clinical evaluation. The identification of functionally
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distinct receptor isoforms of EPO mediating independent
hematopoietic and tissue-protective effects has enabled the
development of compounds specifically tailored for tissue-
protective use. The likely requirement of high doses EPO
needed to achieve adequate drug concentration in some
tissues, coupled with the well-known dose-dependent
potential adverse effects of EPO, especially thrombosis,
suggest that the specifically engineered non-erythropoietic
tissue-protective agents could offer significant advantages
over EPO itself.
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